Tevogen Bio Holdings Inc (TVGN)

$0.30 0.00 (-1.22%)
Market Cap 60.34M
Revenue (ttm) 0.00
Net Income (ttm) -13.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.56
Volume 675,000
Avg Vol 978,968
Day's Range N/A - N/A
Shares Out 198.69M
Stochastic %K 21%
Beta -0.79
Analysts Strong Sell
Price Target $5.00

Company Profile

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 pati...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 838 6436
Website: tevogen.com
Address:
15 Independence Boulevard, Suite #410, Warren, United States
zshortcut
zshortcut Jan. 30 at 10:55 PM
$TVGN can someone fill me in where they have excess money for a dividend?
0 · Reply
MrAlientrader
MrAlientrader Jan. 30 at 8:51 PM
$TVGN lots new shorts opened position
0 · Reply
JesusIsComingSoon
JesusIsComingSoon Jan. 30 at 8:28 PM
$TVGN They mind as well not even release any news in the first place
0 · Reply
Marketmoverjoe
Marketmoverjoe Jan. 30 at 8:14 PM
$TVGN fluff news if that. timing and amount remain uncertain
0 · Reply
JimBull
JimBull Jan. 30 at 8:01 PM
$TVGN evaluate, 😂😂
0 · Reply
Bacons
Bacons Jan. 29 at 7:57 PM
$TVGN Any RS coming?
2 · Reply
robsmi63
robsmi63 Jan. 28 at 5:44 PM
$TVGN hey Saadi, turn the lights off on your way out.
0 · Reply
Stockcoin
Stockcoin Jan. 27 at 12:10 PM
$TVGN
0 · Reply
Azlvr
Azlvr Jan. 23 at 9:33 PM
$TVGN Review Alejos here. 😬 https://www.trustpilot.com/review/www.jccapitalconsultants.com
0 · Reply
dcme010711
dcme010711 Jan. 22 at 11:06 PM
$TVGN this one is for the patient ones for sure
1 · Reply
Latest News on TVGN
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Jan 30, 2026, 3:00 PM EST - 3 days ago

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

Jan 29, 2026, 2:45 PM EST - 4 days ago

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Jan 12, 2026, 9:00 AM EST - 22 days ago

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Dec 22, 2025, 12:40 PM EST - 6 weeks ago

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Dec 19, 2025, 11:10 AM EST - 6 weeks ago

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock

Dec 11, 2025, 3:15 PM EST - 7 weeks ago

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

Dec 9, 2025, 2:20 PM EST - 7 weeks ago

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Dec 8, 2025, 2:50 PM EST - 2 months ago

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Nov 14, 2025, 2:32 PM EST - 2 months ago

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Nov 5, 2025, 3:20 PM EST - 3 months ago

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Nov 3, 2025, 2:45 PM EST - 3 months ago

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Oct 29, 2025, 12:35 PM EDT - 3 months ago

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Oct 15, 2025, 3:50 PM EDT - 3 months ago

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Sep 25, 2025, 8:30 AM EDT - 4 months ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Sep 23, 2025, 8:30 AM EDT - 4 months ago

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Sep 19, 2025, 3:40 PM EDT - 4 months ago

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Sep 10, 2025, 11:59 AM EDT - 5 months ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Sep 9, 2025, 3:15 PM EDT - 5 months ago

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Sep 8, 2025, 9:27 AM EDT - 5 months ago

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Sep 4, 2025, 3:48 PM EDT - 5 months ago

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Sep 3, 2025, 4:15 PM EDT - 5 months ago

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Aug 27, 2025, 3:20 PM EDT - 5 months ago

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Aug 26, 2025, 2:50 PM EDT - 5 months ago

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Aug 25, 2025, 3:10 PM EDT - 5 months ago

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

Aug 22, 2025, 3:25 PM EDT - 5 months ago

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Aug 19, 2025, 3:40 PM EDT - 5 months ago

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Aug 19, 2025, 12:10 PM EDT - 5 months ago

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Aug 18, 2025, 5:50 PM EDT - 6 months ago

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Aug 18, 2025, 5:15 PM EDT - 6 months ago

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Aug 14, 2025, 3:55 PM EDT - 6 months ago

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Aug 13, 2025, 3:53 PM EDT - 6 months ago

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

Aug 11, 2025, 3:45 PM EDT - 6 months ago

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Aug 11, 2025, 1:24 PM EDT - 6 months ago

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Aug 11, 2025, 11:58 AM EDT - 6 months ago

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Aug 11, 2025, 9:28 AM EDT - 6 months ago

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Aug 8, 2025, 11:37 AM EDT - 6 months ago

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Aug 7, 2025, 9:00 AM EDT - 6 months ago

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Aug 6, 2025, 3:59 PM EDT - 6 months ago

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Aug 5, 2025, 2:32 PM EDT - 6 months ago

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Aug 1, 2025, 3:57 PM EDT - 6 months ago

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion

Aug 1, 2025, 3:30 PM EDT - 6 months ago

Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion

Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision

Jul 30, 2025, 12:41 PM EDT - 6 months ago

Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision

Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare

Jul 28, 2025, 11:52 AM EDT - 6 months ago

Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

Jul 18, 2025, 12:36 PM EDT - 7 months ago

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

Jul 17, 2025, 9:15 AM EDT - 7 months ago

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch

Jul 16, 2025, 11:57 AM EDT - 7 months ago

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch

Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

Jul 14, 2025, 9:30 AM EDT - 7 months ago

Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation

Jul 10, 2025, 3:13 PM EDT - 7 months ago

Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

Jun 30, 2025, 2:28 PM EDT - 7 months ago

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

Jun 18, 2025, 8:30 AM EDT - 8 months ago

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

zshortcut
zshortcut Jan. 30 at 10:55 PM
$TVGN can someone fill me in where they have excess money for a dividend?
0 · Reply
MrAlientrader
MrAlientrader Jan. 30 at 8:51 PM
$TVGN lots new shorts opened position
0 · Reply
JesusIsComingSoon
JesusIsComingSoon Jan. 30 at 8:28 PM
$TVGN They mind as well not even release any news in the first place
0 · Reply
Marketmoverjoe
Marketmoverjoe Jan. 30 at 8:14 PM
$TVGN fluff news if that. timing and amount remain uncertain
0 · Reply
JimBull
JimBull Jan. 30 at 8:01 PM
$TVGN evaluate, 😂😂
0 · Reply
Bacons
Bacons Jan. 29 at 7:57 PM
$TVGN Any RS coming?
2 · Reply
robsmi63
robsmi63 Jan. 28 at 5:44 PM
$TVGN hey Saadi, turn the lights off on your way out.
0 · Reply
Stockcoin
Stockcoin Jan. 27 at 12:10 PM
$TVGN
0 · Reply
Azlvr
Azlvr Jan. 23 at 9:33 PM
$TVGN Review Alejos here. 😬 https://www.trustpilot.com/review/www.jccapitalconsultants.com
0 · Reply
dcme010711
dcme010711 Jan. 22 at 11:06 PM
$TVGN this one is for the patient ones for sure
1 · Reply
Marketmoverjoe
Marketmoverjoe Jan. 22 at 1:13 PM
$TVGN Been jumping around. It was up 9%, now down 3.5%. Is it waking up?
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 21 at 2:50 PM
$TVGN Excellent article that nails exactly where TVGN stands right now. So if you want to update your TVGN knowledge or get acquainted with TVGN, this is a must read. https://everyticker.com/quote/TVGN/analysis/tevogen-bio-s-10b-promise-vs-1m-cash-a-clinical-stage-gamble-on-capital-efficiency
2 · Reply
scottstocks12
scottstocks12 Jan. 17 at 7:39 AM
$TVGN any chance for good news? Is literally anyone optimistic here? I was looking at this over $1…
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 17 at 2:03 AM
$TVGN Current Stock Price: $0.34
0 · Reply
JesusIsComingSoon
JesusIsComingSoon Jan. 14 at 8:14 AM
$DVLT As much I hate to agree, as someone who rode the .48c wave all the way to a dollar. It's hard to have high hopes for a company that is based on talk. Look at $TVGN and how long that suckered investors into a CEO announcing a multi billion dollar pipeline in the next blah blah years. Rode that wave up too and was fun up until the $3 levels from .80c but DLVT needs something more concrete.
0 · Reply
bangbanga
bangbanga Jan. 14 at 4:49 AM
$TVGN scam
0 · Reply
Rachs88
Rachs88 Jan. 13 at 10:18 AM
$TVGN remember last to last year, the CEO posted about a billion dollars sale that's why it shot up to $2 levels. What happened since then? No updates?
0 · Reply
PaulLaurent
PaulLaurent Jan. 13 at 6:36 AM
🚀📈 Top Gainers 📈🚀 AH $ZGM $JG $JYD $TVGN $TCRT
0 · Reply
JesusIsComingSoon
JesusIsComingSoon Jan. 12 at 8:18 PM
$TVGN Just understand when TVGN was at $7, it did one bull run cycle and then dump to .25 cents. If you think this company is worth $60M even at these prices, you are deluded. They are burning cash like no tomorrow and without any revenue. You all got suckered into a pipe dream that may never manifest because the CEO projected billions of dollars in revenue. Now that we are back down at these levels, take the gamble if you think another bull run cycle is about to occur. But I'd bet otherwise. They need cash, they have no revenue, and are burning cash. An RS and Dilution into new lows is the likely scenerio. And this is Pharma BIOTECH company. Know when to walk away and when the show is over.
0 · Reply
JesusIsComingSoon
JesusIsComingSoon Jan. 12 at 8:03 PM
$TVGN Oh, we never seeing these prices for a LONG TIME if ever. Especially if we RS and Dilute... We going down down baby...
0 · Reply
MrAlientrader
MrAlientrader Jan. 12 at 7:48 PM
$TVGN new lows coming
0 · Reply
Marketmoverjoe
Marketmoverjoe Jan. 12 at 3:35 PM
$TVGN SO they blitz you w positive news and it can't hold. always love that about companies. good news equals a drop in share price. I ain't selling, bitches.
2 · Reply